357 related articles for article (PubMed ID: 36497303)
1. SGLT-2 Inhibitors in Cancer Treatment-Mechanisms of Action and Emerging New Perspectives.
Dutka M; Bobiński R; Francuz T; Garczorz W; Zimmer K; Ilczak T; Ćwiertnia M; Hajduga MB
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497303
[TBL] [Abstract][Full Text] [Related]
2. Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes.
Derosa G; Maffioli P
Ther Clin Risk Manag; 2018; 14():1637-1640. PubMed ID: 30237717
[TBL] [Abstract][Full Text] [Related]
3. [Outcome studies on SGLT-2 inhibitors].
Seufert J; Laubner K
Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
[TBL] [Abstract][Full Text] [Related]
4. Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies.
Alshnbari AS; Millar SA; O'Sullivan SE; Idris I
Diabetes Ther; 2020 Sep; 11(9):1947-1963. PubMed ID: 32715425
[TBL] [Abstract][Full Text] [Related]
5. Implications and Economic Impact of Applying International Guidelines and Recommendations to the Management of High-Risk Group of Type 2 Diabetes Mellitus Patients in India.
Fatima Z; Atal S; Joshi R; Sadasivam B
Cureus; 2022 Feb; 14(2):e22141. PubMed ID: 35308676
[TBL] [Abstract][Full Text] [Related]
6. Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.
Mende CW
Curr Med Res Opin; 2017 Mar; 33(3):541-551. PubMed ID: 27977314
[TBL] [Abstract][Full Text] [Related]
7. Impact of SGLT Inhibitors on Multiple Organ Defects in Diabetes.
Asrih M; Gariani K
Curr Diabetes Rev; 2020; 16(5):411-418. PubMed ID: 31702506
[TBL] [Abstract][Full Text] [Related]
8. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence.
Scheen AJ; Paquot N
Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S4-S11. PubMed ID: 25554070
[TBL] [Abstract][Full Text] [Related]
9. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
Woo V; Connelly K; Lin P; McFarlane P
Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
[No Abstract] [Full Text] [Related]
10. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class.
da Silva PN; da Conceição RA; do Couto Maia R; de Castro Barbosa ML
Medchemcomm; 2018 Aug; 9(8):1273-1281. PubMed ID: 30151080
[TBL] [Abstract][Full Text] [Related]
11. SGLT-2 Inhibitor Use in Heart Failure: A Review for Nurses.
March KL; Lukas JG; Berei TJ; Shah SP; Cave BE
Crit Care Nurs Q; 2022 Apr-Jun 01; 45(2):189-198. PubMed ID: 35212658
[TBL] [Abstract][Full Text] [Related]
12. Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
Boeder S; Edelman SV
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):62-77. PubMed ID: 31081593
[TBL] [Abstract][Full Text] [Related]
13. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus.
Riser Taylor S; Harris KB
Pharmacotherapy; 2013 Sep; 33(9):984-99. PubMed ID: 23744749
[TBL] [Abstract][Full Text] [Related]
14. Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews.
Pelletier R; Ng K; Alkabbani W; Labib Y; Mourad N; Gamble JM
Ther Adv Drug Saf; 2021; 12():2042098621989134. PubMed ID: 33552467
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
Schwartz SS; Ahmed I
Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
[TBL] [Abstract][Full Text] [Related]
16. Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis.
Lorenzi M; Ploug UJ; Langer J; Skovgaard R; Zoratti M; Jansen J
Diabetes Ther; 2017 Feb; 8(1):85-99. PubMed ID: 27995594
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus.
Mirabelli M; Chiefari E; Caroleo P; Vero R; Brunetti FS; Corigliano DM; Arcidiacono B; Foti DP; Puccio L; Brunetti A
J Diabetes Res; 2019; 2019():3971060. PubMed ID: 31781664
[TBL] [Abstract][Full Text] [Related]
18. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease.
Aftab S; Vetrivel Suresh R; Sherali N; Daniyal M; Tsouklidis N
Cureus; 2020 Oct; 12(10):e10783. PubMed ID: 33042651
[TBL] [Abstract][Full Text] [Related]
19. Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data.
Patel K; Carbone A
Ann Pharmacother; 2019 Dec; 53(12):1227-1237. PubMed ID: 31226886
[No Abstract] [Full Text] [Related]
20. Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering.
Yanai H; Katsuyama H; Hamasaki H; Adachi H; Moriyama S; Yoshikawa R; Sako A
J Clin Med Res; 2016 Jan; 8(1):10-4. PubMed ID: 26668677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
